Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 3, 2017, Pages 684-690

  Villellas, Cristina ^a   Coeck, Nele ^b   Meehan, Conor J ^b   Lounis, Nacer ^a   De Jong, Bouke ^b   Rigouts, Leen ^b   Andries, Koen ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BEDAQUILINE; CLOFAZIMINE; QUINOLINE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL (TOPIC); DNA SEQUENCE; DRUG EFFECTS; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTI-INFLAMMATORY AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; CLOFAZIMINE; DIARYLQUINOLINES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RIFAMPIN; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85019702149     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw502     Document Type: Article

References (28)

1. Andries K, Villellas C, Coeck N et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014; 9: e102135.
2. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
3. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-81.
4. Huitric E, Verhasselt P, Koul A et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010; 54: 1022-8.
5. Segala E, SougakoffW, Nevejans-Chauffour A et al. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother 2012; 56: 2326-34.
6. Almeida D, Ioerger T, Tyagi S et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2016; 60: 4590-9.
7. Pym AS, Diacon AH, Tang SJ et al. Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564-74.
8. Diacon AH, Pym A, Grobusch MP et al. Multidrug-resistant tuberculosis and culture conversionwith bedaquiline.NEngl JMed2014; 371: 723-32.
9. Torrea G, Coeck N, Desmaretz C et al. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system. J Antimicrob Chemother 2015; 70: 2300-5.
10. Palomino JC,Martin A, CamachoMet al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 2720-2.
11. EUCAST. Bedaquiline Breakpoint. http://www.eucast.org/ast_of_mycobac teria/.
12. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
13. Walker TM, Kohl TA, Omar SV et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015; 15: 1193-202.
14. Seemann T. Snippy: Fast Bacterial Variant Calling From NGS Reads. 2015. https://github.com/tseemann/snippy.
15. Feuerriegel S, Schleusener V, Beckert P et al. PhyResSE: a web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data. J Clin Microbiol 2015; 53: 1908-14.
16. Stucki D, Malla B, Hostettler S et al. Two new rapid SNP-typing methods for classifying Mycobacterium tuberculosis complex into the main phylogenetic lineages. PLoS One 2012; 7: e41253.
17. Wakamoto Y, Dhar N, Chait R et al. Dynamic persistence of antibioticstressedmycobacteria. Science 2013; 339: 91-5.
18. Manina G, Dhar N, McKinney JD. Stress and host immunity amplify Mycobacterium tuberculosis phenotypic heterogeneity and induce nongrowingmetabolically active forms. Cell Host Microbe 2015; 17: 32-46.
19. Gullberg E, Cao S, BergOGet al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog 2011; 7: e1002158.
20. Schwebach JR, JacobsWRJr, Casadevall A. Sterilization ofMycobacterium tuberculosis Erdman samples by antimicrobial fixation in a biosafety level 3 laboratory. JClinMicrobiol 2001; 39: 769-71.
21. Milano A, Pasca MR, Provvedi R et al. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb) 2009; 89: 84-90.
22. Walker TM, Ip CL, Harrell RH et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 2013; 13: 137-46.
23. Somoskovi A, Bruderer V, Homke R et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.Eur Respir J 2015; 45: 554-7.
24. Bloemberg GV, Keller PM, StuckiDet al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis.NEngl JMed2015; 373: 1986-8.
25. Hoffmann H, Kohl TA, Hofmann-Thiel S et al. Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee. Am J Respir Crit Care Med 2016; 193: 337-40.
26. de Knegt GJ, Bruning O, ten Kate MT et al. Rifampicin-induced transcriptome response in rifampicin-resistant Mycobacterium tuberculosis. Tuberculosis (Edinb) 2013; 93: 96-101.
27. Wells RM, Jones CM, Xi Z et al. Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis. PLoS Pathog 2013; 9: e1003120.
28. Fang Z, Sampson SL, Warren RMet al. Iron acquisition strategies inmycobacteria. Tuberculosis (Edinb) 2015; 95: 123-30.